Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Alvorlig akutt underernæring og klinisk utprøving av barn i Mwanza (BRIGHTSAM)

11. november 2026 oppdatert av: Dr George PrayGod, National Institute for Medical Research, Tanzania

BRAIN DEVELOPMENT, GROWTH AND HEALTH IN CHILDREN WITH SEVERE ACUTE MALNUTRITION

This is a randomized clinical trial to learn whether ready-to-use therapeutic foods enriched with choline and docosahexaenoic acid (DHA) together with psychosocial stimulating activities work well to improve child development in children with severe acute malnutrition(SAM). The overall question this trial aims to answer is can the health and development outcomes of children with SAM be improved through optimized nutritional treatment and integrated psychosocial support.

Researchers will compare the new ready-to-use therapeutic food and an integrated psychosocial stimulation to a standard look-alike nutritional supplement that contains no additional nutrients being investigated and the standard nutritional counseling given locally and assess its effects on child development in children with severe acute malnutrition.

Participants will:

  • Be given the trial interventions which will be delivered over 12 weeks
  • After the 12 weeks of intervention, participants will return for outcome evaluations (week 12 study visit), which will be repeated at follow-up visits after 24 and 48 weeks.

Studieoversikt

Detaljert beskrivelse

Background Estimated, 13.6 million children were affected by severe acute malnutrition (SAM) in 2022. Early childhood is a critical period of brain development and children exposed to malnutrition in early life have poorer school performance and lower income in adult life. Introduction of Ready to use therapeutic foods (RUTF) has greatly improved the nutritional recovery of children with SAM. However, SAM remains associated with adverse effects on child cognitive and social development. The balance in the RUTF between polyunsaturated n-6 and n-3 essential fatty acids (EFAs) in RUTF has been questioned. Essential fatty acid (EFA) status is associated with child development, and children given the standard RUTF do not improve their n-3 EFA status after recovery.

A trial in Malawi found a positive effect on cognitive scores six months after completing nutritional therapy with RUTF with added preformed docosahexaenoic acid (DHA), a long-chain polyunsaturated fatty acid (PUFA) of the n-3 series, which is essential for neural growth. There is also a potential for improving the content of other nutrients of importance for neurodevelopment in early childhood like choline, which is essential for neurotransmitter synthesis and phospholipids in the brain. Studies have indicated a synergistic relationship between n-3 EFAs and choline, suggesting that low levels of one or both may negatively impact cognition.

Deficits in child development associated with SAM are not only caused by inadequate diets. Families exposed to malnutrition are often affected by psychological distress, consequently children are likely to be offered little stimulation and responsive care. However, in practice, support for psychosocial stimulation and responsive caregiving is rarely offered during hospital-based treatment, and it is still not included in the guidelines for community-based treatment of SAM. The intensity of this intervention is difficult under the constraints of most health services in low- and middle-income countries (LMIC). More recent packages for promoting responsive care have shown some effects, but often not when implemented at scale or within systems of care.

In this study we hypothesize that optimized nutritional treatment and integrated psychosocial support can improve the health and development outcomes of children with SAM.

Specific objectives:

  1. to assess the effects of a modified RUTF and psychosocial stimulation, individually and combined, on attention, cognitive, motor, language and psycho-emotional development in children treated for SAM;
  2. to investigate the pathways of intervention effects on cognitive development by assessing the role of DHA and choline status in the child as well as caregiver factors which include caregiver-child interaction, home stimulation and maternal psychological distress;
  3. to assess how, why and for whom the modified RUTF and psychosocial interventions work within the trial context, perceptions of their feasibility of implementation within the routine health system, and the climate and environmental sustainability of interventions.

Methods:

This trial is designed as a 2x2 factorial randomized clinical trial to assess the effects of DHA and choline enriched vs. standard RUTF and psychosocial stimulation vs. standard counselling in management of SAM. Participants will be individually randomised to nutritional intervention arms and clusters will be randomized to psychosocial intervention arms.

The interventions will be delivered over a period of 12 weeks. After enrolment and baseline data collection, participants will receive their first RUTF sachets. They will then be requested to return to the study site for a total of seven visits during the intervention period to receive interventions. After the 12 weeks of intervention, participants will return for outcome evaluations (week 12 study visit), which will be repeated at follow-up visits after 24 and 48 weeks. The study will take place in Mwanza region, Tanzania. The trial will include children with uncomplicated SAM aged 6-36 months from eight health care facilities in Ilemela municipality, Nyamagana municipality and Magu district.

Outcomes:

The primary outcomes is the change in child development scores, which will be assessed at baseline, 12, 24 and 48 weeks and compared with intervention groups. These will assess gross, fine motor, language and psycho -emotional skills by validated tool called (MDAT) Malawi Development Assessment Tool) and neurocognitive function will be accessed by eye-tracking. Secondary outcomes will allow us to assess proximate effects of the interventions, which may mediate long-term effects on development

Analysis:

The primary analysis will be based on the intention-to-treat principle using available case data. The analysis will assess intervention effects based on the 2x2 factorial design by comparing changes in outcomes between baseline and intervention endline (i.e., 12 weeks) using a linear regression model adjusted for sex, age and month of inclusion to account for possible seasonal effects.

Secondary analysis will include assessment of intervention effects at 24- and 48-weeks follow-up using a linear mixed model to include repeated measurements. The models will include the baseline value of the outcome as fixed effect and participant as random effect to account for the correlation between measurements from the same participant. These models will also include adjustment for other variables as appropriate.

Secondary analyses will include per-protocol analyses to assess effects within groups with high compliance with the interventions

Ethics:

Ethical approval has been sought from the Medical Research Coordinating Committee (MRCC) of the National Institute for Medical Research in Tanzania and the London School of Hygiene and Tropical Medicine ethics committee.

Studietype

Intervensjonell

Registrering (Faktiske)

806

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Mwanza, Tanzania
        • National Institute for Medical Research

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

6 måneder til 3 år (Barn)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Age from 6-36 months.
  2. Consent given by a caregiver older than 18 years.
  3. Diagnosed with severe acute malnutrition (MUAC<115 mm, or WHZ ≤-3 or bipedal pitting edema).
  4. Eligible for RUTF treatment (expanded below).

Exclusion Criteria:

  1. Conditions preventing the child from receiving interventions, e.g., peanut butter allergy or cleft palate.
  2. Moderate or severe disability which significantly affects normal child development (e.g., cerebral palsy or hydrocephalus), identified using a standardized screening form.
  3. Children of families not living in the area or planning to move from the area within the follow-up period

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Faktoriell oppgave
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: eRUTF

Choline and DHA enriched Ready to use therapeutic foods

DHA & Choline enriched RUTF The modified RUTF is a peanut butter paste that contains vegetable oil, skim milk powder, carbohydrates, vitamins, and minerals the same nutrients which are the same as the standard RUTF but is fortified additionally with 250 mg of choline and 200 mg of preformed DHA per 92-gram sachet.

Standard RUTF The standard RUTF used in the BrightSAM trial is a peanut butter paste with vegetable oil, skim milk powder, carbohydrates, vitamins, and minerals that is intended to cover the child's total daily nutritional needs. Standard RUTF will be manufactured in compliance with the specifications recommended by the Codex Alimentarius Commission17.

Placebo komparator: sRUTF

Standard ready-to-use therapeutic foods

DHA & Choline enriched RUTF The modified RUTF is a peanut butter paste that contains vegetable oil, skim milk powder, carbohydrates, vitamins, and minerals the same nutrients which are the same as the standard RUTF but is fortified additionally with 250 mg of choline and 200 mg of preformed DHA per 92-gram sachet.

Standard RUTF The standard RUTF used in the BrightSAM trial is a peanut butter paste with vegetable oil, skim milk powder, carbohydrates, vitamins, and minerals that is intended to cover the child's total daily nutritional needs. Standard RUTF will be manufactured in compliance with the specifications recommended by the Codex Alimentarius Commission17.

Eksperimentell: PS

Psychosocial stimulation

The psychosocial intervention has been developed and piloted for this study as a context-relevant adaptation from the WHO/UNICEF Care for Child Development package. It will be delivered in group sessions, where the primary caregiver will attend along with the child participating in the trial.

During seven sessions of approximately two hours, caregivers will be trained on a variety of subjects which include; the first four sessions will be introductory and provide the basics of nutrition, the basics of psychosocial stimulation, and play and communication practices. We will build on the increasing experience of the caregivers and provide a deeper understanding of early child development.

Standard nutritional counseling will adhere to national guidelines for pediatric management of severe acute malnutrition including nutritional counseling and psychosocial stimulation.

Placebo komparator: sNC

Standard nutritional counseling and psychosocial stimualtion

The psychosocial intervention has been developed and piloted for this study as a context-relevant adaptation from the WHO/UNICEF Care for Child Development package. It will be delivered in group sessions, where the primary caregiver will attend along with the child participating in the trial.

During seven sessions of approximately two hours, caregivers will be trained on a variety of subjects which include; the first four sessions will be introductory and provide the basics of nutrition, the basics of psychosocial stimulation, and play and communication practices. We will build on the increasing experience of the caregivers and provide a deeper understanding of early child development.

Standard nutritional counseling will adhere to national guidelines for pediatric management of severe acute malnutrition including nutritional counseling and psychosocial stimulation.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in MDAT scores
Tidsramme: Assessed at baseline, 12, 24 and 48 weeks

Development will be assessed by validated methods and include:

Gross motor, fine motor, language, and psycho-emotional skills assessed by the Malawi Development assessment tool (MDAT)

Assessed at baseline, 12, 24 and 48 weeks
Change in eye tracking scores
Tidsramme: Baseline, 12, 24 and 48 weeks

Neurocognitive function assessed by eye-tracking technique

Baseline, 12, 24 and 48 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Level of caregiver stimulation and support
Tidsramme: Assessed at baseline, 12, 24 and 48 weeks

Caregiver stimulation and support assessed by Observations of Mother and Child Interactions (OMCI) questionnaire

Assessed at baseline, 12, 24 and 48 weeks
Fatty acid composition
Tidsramme: at baseline and at week 12, and week 48

- Fatty acid composition assessed by gas chromatography

at baseline and at week 12, and week 48
Mid upper arm circumference (MUAC)
Tidsramme: Baseline, weekly, 12, 24 and 48 weeks

- MUAC assessed using non-stretchable tape measure

Baseline, weekly, 12, 24 and 48 weeks
Mortality
Tidsramme: 12, 24 and 48 weeks

Proportion of children who die during follow-up

12, 24 and 48 weeks
Process evaluation
Tidsramme: Interviews will be conducted after the last PS session ( Week 11) , and where possible, again with the same caregivers at long term follow-up (week 24 and 48).

The process evaluation will examine the following aspects of the interventions:

  • Implementation
  • Mechanisms
  • Context
  • Acceptability
  • Feasibility of implementation within the health system
  • Programme theory
Interviews will be conducted after the last PS session ( Week 11) , and where possible, again with the same caregivers at long term follow-up (week 24 and 48).
Levels of choline
Tidsramme: Baseline, 12, 24 and 48 weeks

Levels of choline and related metabolites assessed by mass spectrometry

Baseline, 12, 24 and 48 weeks
C-reactive protein (CRP)
Tidsramme: Baseline, 12, 24 and 48 weeks

Serum CRP assessed as a marker of systemic inflammation

Baseline, 12, 24 and 48 weeks
Ferritin
Tidsramme: Baseline, 12, 24 and 48 weeks

Serum ferritin assessed as marker of iron status

Baseline, 12, 24 and 48 weeks
Level of Alanine transaminase
Tidsramme: Baseline, 12, 24 and 48 weeks

Serum alanine transaminase as a marker of liver function

Baseline, 12, 24 and 48 weeks
Level of Aspartate transaminase
Tidsramme: Baseline, 12, 24 and 48 weeks

Serum aspartate transaminase assessed as a marker of liver function

Baseline, 12, 24 and 48 weeks
Level of maternal psychological distress
Tidsramme: Baseline, 12, 24 and 48 weeks

Maternal psychological distress assessed by Patient Health Questionnaire 9 (PHQ-9)

Baseline, 12, 24 and 48 weeks
Status of the learning environment
Tidsramme: Baseline, 12, 24 and 48 weeks

The status of learning environment assessed by the Family Care Indicators (FCI) questionnaire

Baseline, 12, 24 and 48 weeks
Status of maternal social support framework
Tidsramme: Baseline, 12, 24 and 48 weeks

The status of maternal social support framework assessed by the Multidimensional Scale of Perceived Social Support questionnaire

Baseline, 12, 24 and 48 weeks
Morbidity
Tidsramme: 12, 24 and 48 weeks

. Proportion of children with one or multiple illness episodes during follow-up

12, 24 and 48 weeks
- Weight-for-height z-score (WHZ)
Tidsramme: Baseline, 12, 24 and 48 weeks

- Weight-for-height z-score (WHZ) based on length/height (m) and weight (kg) measurements'

Baseline, 12, 24 and 48 weeks
Height-for-age z-score (HAZ) , based on length/height and age)
Tidsramme: Baseline, 12, 24 and 48 weeks

Height-for-age z-score (HAZ) assessed based on length/height (m) and age (month)

Baseline, 12, 24 and 48 weeks
Rate of nutritional recovery at the end of intervention period
Tidsramme: 12

Rate of nutritional recovery at the end of intervention period, defined as WHZ > -2 and MUAC > 125 mm, and no bilateral pitting oedema for two weeks

12
Proportion relapsing to moderate acute malnutrition (MAM) after recovery
Tidsramme: 12 weeks

Proportion relapsing to moderate acute malnutrition (MAM) after recovery, measured as WHZ ≤ -2 and >-3 or MUAC ≤ 125 and >115mm)

12 weeks
Proportion relapsing to SAM after recovery
Tidsramme: Any time point, 24 and 48 weeks

Proportion relapsing to SAM after recovery, measured as WHZ <-3, MUAC <115mm or presence of nutritional oedema, assessed at any caregiver-initiated contacts to the study site at any point during the 48 weeks of follow-up and at study visits at 24 and 48 weeks

Any time point, 24 and 48 weeks
Implementation evaluation
Tidsramme: Interviews will be conducted after the last PS session ( Week 11) , and where possible, again with the same caregivers at long term follow-up (week 24 and 48).

The implementation component will assess

  • The fidelity of implementation of each component of the intervention,
  • The dose (amount, frequency) of each component delivered to the children,
  • Any adaptations to the intervention and why these were made,
  • The reach of the interventions, provider and caregiver experience
  • Perceptions, mechanisms and any unintended consequences.
Interviews will be conducted after the last PS session ( Week 11) , and where possible, again with the same caregivers at long term follow-up (week 24 and 48).

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: George PrayGod, MD, PhD, National Institute for Medical Research
  • Hovedetterforsker: Mette Olsen, MSc, PhD, Copenhagen University Hospital, Rigshospitalet

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

25. februar 2025

Primær fullføring (Faktiske)

31. august 2026

Studiet fullført (Faktiske)

31. august 2026

Datoer for studieregistrering

Først innsendt

3. desember 2024

Først innsendt som oppfylte QC-kriteriene

13. januar 2025

Først lagt ut (Faktiske)

17. januar 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

11. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • DFC file no. 23-13-RH
  • DFC file no. 23-13-RH (Annet stipend/finansieringsnummer: DANIDA under Danish Ministry of Foreign Affairs)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere